**Chapter 3**

*Hormone Therapy and Replacement in Cancer and Aging-Related Diseases*

[62] Zhou Q, Shen L, Liu C, Liu C, Chen H, Liu J. The effects of estradiol and glucocorticoid on human osteosarcoma cells: Similarities and differences. Anticancer Research. 2016;**36**:1683-1691

BAX/BCL-2 and reducing pERK1/2. Anticancer Research. 2012;**32**:1181-1191

[56] Wang W, Belosay A, Yang X, Hartman JA, Song H, Iwaniec UT, et al. Effects of letrozole on breast cancer micro-metastatic tumor growth in bone and lung in mice inoculated with murine 4T1 cells. Clinical & Experimental Metastasis. 2016;**33**:475-485. DOI: 10.1007/s10585-016-9792-z

[57] Ariazi EA, Leitao A, Oprea TI, Chen B, Louis T, Bertucci AM, et al. Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen. Molecular Cancer Therapeutics. 2007;**6**:2817-2827. DOI: 10.1158/1535-7163.mct-07-0312

[58] Bartels S, Christgen M, Luft A, Persing S, Jödecke K, Lehmann U, et al. Estrogen receptor (ESR1) mutation in bone metastases from breast cancer. Modern Pathology. 2018;**31**:56-61. DOI:

[59] Kang E, Cho JH, Choi J-H, Yoo H-W. Etiology and therapeutic outcomes of children with gonadotropinindependent precocious puberty. Annals of Pediatric Endocrinology & Metabolism. 2016;**21**:136. DOI: 10.6065/

[60] Gorska M, Wyszkowska RM, Kuban-Jankowska A, Wozniak M. Impact of apparent antagonism of estrogen receptor β by

fulvestrant on anticancer activity of 2-methoxyestradiol. Anticancer Research [Internet]. 2016;**36**:2217-2226. Available from: http://www.ncbi.nlm.

[61] Holen I, Walker M, Nutter F, Fowles A, Evans CA, Eaton CL, et al. Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo. Clinical & Experimental Metastasis. 2016;**33**:211-224. DOI: 10.1007/s10585-015-9770-x

nih.gov/pubmed/27127126

10.1038/modpathol.2017.95

apem.2016.21.3.136

**34**
